

<b>Audit Review Table</b>				
Aetna Better Health of Texas (Org ID: 19734, SubID: 11745, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)				
Measurement Year - 2017; Date & Timestamp - 6/27/2018 2:10:34 PM				
The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
<b>Effectiveness of Care: Prevention and</b>				
<b>Adult BMI Assessment (aba)</b>		84.91%	R	Reportable
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)</b>				
<i>BMI Percentile</i>		66.42%	R	Reportable
<i>Counseling for Nutrition</i>		72.51%	R	Reportable
<i>Counseling for Physical Activity</i>		61.31%	R	Reportable
<b>Childhood Immunization Status (cis)</b>				
<i>DTaP</i>		73.48%	R	Reportable
<i>IPV</i>		86.37%	R	Reportable
<i>MMR</i>		89.05%	R	Reportable
<i>HiB</i>		87.10%	R	Reportable
<i>Hepatitis B</i>		87.83%	R	Reportable
<i>VZV</i>		89.29%	R	Reportable
<i>Pneumococcal Conjugate</i>		77.13%	R	Reportable
<i>Hepatitis A</i>		88.08%	R	Reportable
<i>Rotavirus</i>		70.07%	R	Reportable
<i>Influenza</i>		43.55%	R	Reportable
<i>Combination #2</i>		70.80%	R	Reportable
<i>Combination #3</i>		68.13%	R	Reportable
<i>Combination #4</i>		67.64%	R	Reportable
<i>Combination #5</i>		59.12%	R	Reportable
<i>Combination #6</i>		37.23%	R	Reportable
<i>Combination #7</i>		58.88%	R	Reportable
<i>Combination #8</i>		37.23%	R	Reportable
<i>Combination #9</i>		33.82%	R	Reportable
<i>Combination #10</i>		33.82%	R	Reportable
<b>Immunizations for Adolescents (ima)</b>				
<i>Meningococcal</i>		81.51%	R	Reportable

<i>Tdap</i>		84.43%	R	Reportable
<i>HPV</i>		25.79%	R	Reportable
<i>Combination #1</i>		79.81%	R	Reportable
<i>Combination #2</i>		22.87%	R	Reportable
<b>Lead Screening in Children (lsc)</b>		54.01%	R	Reportable
<b>Breast Cancer Screening (bcs)</b>		65.38%	NA	Small Denominator
<b>Cervical Cancer Screening (ccs)</b>		67.40%	R	Reportable
<b>Chlamydia Screening in Women (chl)</b>				
<i>16-20 Years</i>		52.55%	R	Reportable
<i>21-24 Years</i>		66.67%	R	Reportable
<i>Total</i>		55.64%	R	Reportable
<b>Effectiveness of Care: Respiratory</b>				
<b>Appropriate Testing for Children with Pharyngitis (cwp)</b>	Y	78.22%	R	Reportable
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)</b>		0.00%	NA	Small Denominator
<b>Pharmacotherapy Management of COPD Exacerbation (pce)</b>	Y			
<i>Systemic Corticosteroid</i>		78.57%	NA	Small Denominator
<i>Bronchodilator</i>		78.57%	NA	Small Denominator
<b>Medication Management for People With Asthma (mma)</b>	Y			
<i>5-11 Years: Medication Compliance 50%</i>		45.78%	R	Reportable
<i>5-11 Years: Medication Compliance 75%</i>		20.78%	R	Reportable
<i>12-18 Years: Medication Compliance 50%</i>		36.72%	R	Reportable
<i>12-18 Years: Medication Compliance 75%</i>		18.75%	R	Reportable
<i>19-50 Years: Medication Compliance 50%</i>		88.89%	NA	Small Denominator
<i>19-50 Years: Medication Compliance 75%</i>		50.00%	NA	Small Denominator
<i>51-64 Years: Medication Compliance 50%</i>			NA	Small Denominator
<i>51-64 Years: Medication Compliance 75%</i>			NA	Small Denominator
<i>Total: Medication Compliance 50%</i>		44.98%	R	Reportable
<i>Total: Medication Compliance 75%</i>		21.34%	R	Reportable
<b>Asthma Medication Ratio (amr)</b>	Y			
<i>5-11 Years</i>		60.62%	R	Reportable
<i>12-18 Years</i>		47.52%	R	Reportable

19-50 Years		61.90%	NA	Small Denominator
51-64 Years			NA	Small Denominator
Total		57.09%	R	Reportable
<b>Effectiveness of Care: Cardiovascular</b>				
<b>Controlling High Blood Pressure (cbp)</b>		48.11%	R	Reportable
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)</b>	Y	50.00%	NA	Small Denominator
<b>Statin Therapy for Patients With Cardiovascular Disease (spc)</b>	Y			
Received Statin Therapy: 21-75 Years (Male)		100.00%	NA	Small Denominator
Statin Adherence 80%: 21-75 Years (Male)		100.00%	NA	Small Denominator
Received Statin Therapy: 40-75 Years (Female)		83.33%	NA	Small Denominator
Statin Adherence 80%: 40-75 Years (Female)		40.00%	NA	Small Denominator
Received Statin Therapy: Total		87.50%	NA	Small Denominator
Statin Adherence 80%: Total		57.14%	NA	Small Denominator
<b>Effectiveness of Care: Diabetes</b>				
<b>Comprehensive Diabetes Care (cdc)</b>				
Hemoglobin A1c (HbA1c) Testing		85.04%	R	Reportable
HbA1c Poor Control (>9.0%)		59.40%	R	Reportable
HbA1c Control (<8.0%)		29.91%	R	Reportable
HbA1c Control (<7.0%)			NQ	Not Required
Eye Exam (Retinal) Performed		47.86%	R	Reportable
Medical Attention for Nephropathy		87.18%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		58.97%	R	Reportable
<b>Statin Therapy for Patients With Diabetes (spd)</b>	Y			
Received Statin Therapy		44.19%	R	Reportable
Statin Adherence 80%		47.37%	NA	Small Denominator
<b>Effectiveness of Care: Musculoskeletal</b>				
<b>Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)</b>	Y	75.00%	NA	Small Denominator
<b>Effectiveness of Care: Behavioral</b>				
<b>Antidepressant Medication Management (amm)</b>	Y			
Effective Acute Phase Treatment		48.16%	R	Reportable
Effective Continuation Phase Treatment		35.10%	R	Reportable
<b>Follow-Up Care for Children Prescribed ADHD Medication (add)</b>	Y			

<i>Initiation Phase</i>		38.16%	R	Reportable
<i>Continuation and Maintenance (C&amp;M) Phase</i>		72.88%	R	Reportable
<b>Follow-Up After Hospitalization for Mental Illness (fuh)</b>	Y			
<i>30-Day Follow-Up</i>		54.20%	R	Reportable
<i>7-Day Follow-Up</i>		32.32%	R	Reportable
<b>Follow-Up After Emergency Department Visit for Mental Illness (fum)</b>	Y			
<i>30-Day Follow-Up</i>		45.66%	R	Reportable
<i>7-Day Follow-Up</i>		32.37%	R	Reportable
<b>Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fua)</b>	Y			
<i>30-Day Follow-Up: 13-17 Years</i>		4.17%	NA	Small Denominator
<i>7-Day Follow-Up: 13-17 Years</i>		4.17%	NA	Small Denominator
<i>30-Day Follow-Up: 18+ Years</i>		6.12%	R	Reportable
<i>7-Day Follow-Up: 18+ Years</i>		6.12%	R	Reportable
<i>30-Day Follow-Up: Total</i>		5.48%	R	Reportable
<i>7-Day Follow-Up: Total</i>		5.48%	R	Reportable
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)</b>	Y	87.06%	R	Reportable
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)</b>		100.00%	NA	Small Denominator
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)</b>			NA	Small Denominator
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)</b>	Y	50.00%	NA	Small Denominator
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)</b>	Y			
<i>1-5 Years</i>		0.00%	NA	Small Denominator
<i>6-11 Years</i>		28.92%	R	Reportable
<i>12-17 Years</i>		40.74%	R	Reportable

<i>Total</i>		32.57%	R	Reportable
<b>Effectiveness of Care: Medication</b>				
<b>Annual Monitoring for Patients on Persistent Medications (mpm)</b>	Y			
<i>ACE Inhibitors or ARBs</i>		94.63%	R	Reportable
<i>Diuretics</i>		89.00%	R	Reportable
<i>Total</i>		92.37%	R	Reportable
<b>Effectiveness of Care:</b>				
<b>Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)</b>		0.63%	R	Reportable
<b>Appropriate Treatment for Children With URI (uri)</b>	Y	92.20%	R	Reportable
<b>Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)</b>	Y	12.05%	R	Reportable
<b>Use of Imaging Studies for Low Back Pain (lbp)</b>		66.49%	R	Reportable
<b>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)</b>	Y			
<i>1-5 Years</i>		0.00%	NA	Small Denominator
<i>6-11 Years</i>		1.69%	R	Reportable
<i>12-17 Years</i>		0.00%	R	Reportable
<i>Total</i>		0.83%	R	Reportable
<b>Use of Opioids at High Dosage (uod)</b>	Y	33.33	R	Reportable
<b>Use of Opioids From Multiple Providers (uop)</b>	Y			
<i>Multiple Prescribers</i>		364.53	R	Reportable
<i>Multiple Pharmacies</i>		96.06	R	Reportable
<i>Multiple Prescribers and Multiple Pharmacies</i>		73.89	R	Reportable
<b>Access/Availability of Care</b>				
<b>Adults' Access to Preventive/Ambulatory Health Services (aap)</b>				
<i>20-44 Years</i>		80.57%	R	Reportable
<i>45-64 Years</i>		84.27%	R	Reportable
<i>65+ Years</i>			NA	Small Denominator
<i>Total</i>		81.13%	R	Reportable
<b>Children and Adolescents' Access to Primary Care Practitioners (cap)</b>				

12-24 Months		96.77%	R	Reportable
25 Months - 6 Years		87.51%	R	Reportable
7-11 Years		90.20%	R	Reportable
12-19 Years		86.35%	R	Reportable
<b>Annual Dental Visit (adv)</b>	N			
2-3 Years			NB	No Benefit
4-6 Years			NB	No Benefit
7-10 Years			NB	No Benefit
11-14 Years			NB	No Benefit
15-18 Years			NB	No Benefit
19-20 Years			NB	No Benefit
Total			NB	No Benefit
<b>Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)</b>	Y			
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>		50.00%	NA	Small Denominator
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>		21.43%	NA	Small Denominator
<i>Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>		33.33%	NA	Small Denominator
<i>Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>		0.00%	NA	Small Denominator
<i>Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years</i>		62.50%	R	Reportable
<i>Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years</i>		23.75%	R	Reportable
<i>Total: Initiation of AOD Treatment: 13-17 Years</i>		58.89%	R	Reportable
<i>Total: Engagement of AOD Treatment: 13-17 Years</i>		22.22%	R	Reportable
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years</i>		36.76%	R	Reportable
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years</i>		13.24%	R	Reportable
<i>Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years</i>		34.25%	R	Reportable
<i>Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years</i>		16.44%	R	Reportable

<i>Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years</i>		41.01%	R	Reportable
<i>Other drug abuse or dependence: Engagement of AOD Treatment: 18+ Years</i>		11.98%	R	Reportable
<i>Total: Initiation of AOD Treatment: 18+ Years</i>		37.61%	R	Reportable
<i>Total: Engagement of AOD Treatment: 18+ Years</i>		13.43%	R	Reportable
<i>Alcohol abuse or dependence: Initiation of AOD Treatment: Total</i>		39.02%	R	Reportable
<i>Alcohol abuse or dependence: Engagement of AOD Treatment: Total</i>		14.63%	R	Reportable
<i>Opioid abuse or dependence: Initiation of AOD Treatment: Total</i>		34.21%	R	Reportable
<i>Opioid abuse or dependence: Engagement of AOD Treatment: Total</i>		15.79%	R	Reportable
<i>Other drug abuse or dependence: Initiation of AOD Treatment: Total</i>		46.80%	R	Reportable
<i>Other drug abuse or dependence: Engagement of AOD Treatment: Total</i>		15.15%	R	Reportable
<i>Total: Initiation of AOD Treatment: Total</i>		42.12%	R	Reportable
<i>Total: Engagement of AOD Treatment: Total</i>		15.29%	R	Reportable
<b>Prenatal and Postpartum Care (ppc)</b>				
<i>Timeliness of Prenatal Care</i>		85.89%	R	Reportable
<i>Postpartum Care</i>		71.29%	R	Reportable
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)</b>	Y			
<i>1-5 Years</i>		54.55%	NA	Small Denominator
<i>6-11 Years</i>		48.65%	R	Reportable
<i>12-17 Years</i>		41.79%	R	Reportable
<i>Total</i>		46.05%	R	Reportable
<b>Utilization</b>				
<b>Well-Child Visits in the First 15 Months of Life (w15)</b>				
<i>0 Visits</i>		0.97%	R	Reportable
<i>1 Visit</i>		1.70%	R	Reportable
<i>2 Visits</i>		2.19%	R	Reportable
<i>3 Visits</i>		4.14%	R	Reportable
<i>4 Visits</i>		10.22%	R	Reportable
<i>5 Visits</i>		17.27%	R	Reportable

6+ Visits		63.50%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)		76.64%	R	Reportable
Adolescent Well-Care Visits (awc)		57.18%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable
Ambulatory Care: Dual Eligibles (ambb)			NQ	Not Required
Ambulatory Care: Disabled (ambc)			NQ	Not Required
Ambulatory Care: Other (ambd)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)			NQ	Not Required
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)			NQ	Not Required
Identification of Alcohol and Other Drug Services: Total (iada)	Y		R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y		NQ	Not Required
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y		NQ	Not Required
Identification of Alcohol and Other Drug Services: Other (iadd)	Y		NQ	Not Required
Mental Health Utilization: Total (mpta)	Y		R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y		NQ	Not Required
Mental Health Utilization: Disabled (mptc)	Y		NQ	Not Required
Mental Health Utilization: Other (mptd)	Y		NQ	Not Required
Antibiotic Utilization: Total (abxa)	Y		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y		NQ	Not Required
Antibiotic Utilization: Disabled (abxc)	Y		NQ	Not Required
Antibiotic Utilization: Other (abxd)	Y		NQ	Not Required
Standardized Healthcare-Associated Infection Ratio (hai)			NQ	Not Required

Risk Adjusted Utilization				
Plan All-Cause Readmissions (pcr)			R	Reportable
Health Plan Descriptive				
Board Certification (bcr)			NQ	Not Required
Enrollment by Product Line: Total (enpa)			R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)			NQ	Not Required
Enrollment by Product Line: Disabled (enpc)			NQ	Not Required
Enrollment by Product Line: Other (enpd)			NQ	Not Required
Enrollment by State (ebs)			R	Reportable
Language Diversity of Membership (ldm)			R	Reportable
Race/Ethnicity Diversity of Membership (rdm)			R	Reportable
Total Membership (tln)			R	Reportable
Measures Collected using Electronic				
Depression Screening and Follow-Up for Adolescents and Adults (dsf)				
<i>Depression Screening: Total Total</i>			NR	Not Reported
<i>Follow-up on Positive Screen: Total Total</i>			NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (dms)				
<i>Utilization of PHQ-9: Total Total</i>			NR	Not Reported
Depression and Remission or Response for Adolescents and Adults (drr)				
<i>Follow-up PHQ-9: Total Total</i>			NR	Not Reported
<i>Depression Remission: Total Total</i>			NR	Not Reported
<i>Depression Response: Total Total</i>			NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)				
<i>Alcohol Use Screening: Total Total</i>			NR	Not Reported
<i>Counseling or Other Follow-up Postive Screen: Total Total</i>			NR	Not Reported